126 related articles for article (PubMed ID: 38344808)
81. Kinesin family member 3A stimulates cell proliferation, migration, and invasion of bladder cancer cells in vitro and in vivo.
Zhou Q; Yu J; Zheng Q; Wu T; Ji Z; Zhuo Y
FEBS Open Bio; 2021 May; 11(5):1487-1496. PubMed ID: 31774623
[TBL] [Abstract][Full Text] [Related]
82. Development of a novel prognostic signature based on single-cell combined bulk RNA analysis in breast cancer.
Xiao Y; Hu G; Xie N; Yin L; Pan Y; Liu C; Lou S; Zhu C
J Gene Med; 2024 Feb; 26(2):e3673. PubMed ID: 38404059
[TBL] [Abstract][Full Text] [Related]
83. MCAK associates with the tips of polymerizing microtubules.
Moore AT; Rankin KE; von Dassow G; Peris L; Wagenbach M; Ovechkina Y; Andrieux A; Job D; Wordeman L
J Cell Biol; 2005 May; 169(3):391-7. PubMed ID: 15883193
[TBL] [Abstract][Full Text] [Related]
84. K-loop insertion restores microtubule depolymerizing activity of a "neckless" MCAK mutant.
Ovechkina Y; Wagenbach M; Wordeman L
J Cell Biol; 2002 Nov; 159(4):557-62. PubMed ID: 12446739
[TBL] [Abstract][Full Text] [Related]
85. [Pan-cancer analysis of ubiquitin-specific protease 7 and its expression changes in the carcinogenesis of scar ulcer].
Zhang SY; Ruan JJ; Jin DM; Chen N; Xie WG; Ruan QF
Zhonghua Shao Shang Yu Chuang Mian Xiu Fu Za Zhi; 2023 Jun; 39(6):518-526. PubMed ID: 37805766
[No Abstract] [Full Text] [Related]
86. Identification of Hub Genes and Their Correlation With Immune Infiltration Cells in Hepatocellular Carcinoma Based on GEO and TCGA Databases.
Huang R; Liu J; Li H; Zheng L; Jin H; Zhang Y; Ma W; Su J; Wang M; Yang K
Front Genet; 2021; 12():647353. PubMed ID: 33995482
[TBL] [Abstract][Full Text] [Related]
87. SCF
Schweiggert J; Habeck G; Hess S; Mikus F; Beloshistov R; Meese K; Hata S; Knobeloch KP; Melchior F
EMBO J; 2021 Sep; 40(18):e107735. PubMed ID: 34368969
[TBL] [Abstract][Full Text] [Related]
88. The role of long non-coding RNA AFAP1-AS1 in human malignant tumors.
Ji D; Zhong X; Jiang X; Leng K; Xu Y; Li Z; Huang L; Li J; Cui Y
Pathol Res Pract; 2018 Oct; 214(10):1524-1531. PubMed ID: 30173945
[TBL] [Abstract][Full Text] [Related]
89. Comprehensive analysis of 33 human cancers reveals clinical implications and immunotherapeutic value of the solute carrier family 35 member A2.
Xu S; Chen X; Fang J; Chu H; Fang S; Zeng L; Ma H; Zhang T; Chen Y; Wang T; Zhang X; Shen T; Zheng Y; Xu D; Lu Z; Pan Y; Liu Y
Front Immunol; 2023; 14():1155182. PubMed ID: 37275857
[TBL] [Abstract][Full Text] [Related]
90. Galectin-9 Expression Predicts Favorable Clinical Outcome in Solid Tumors: A Systematic Review and Meta-Analysis.
Zhou X; Sun L; Jing D; Xu G; Zhang J; Lin L; Zhao J; Yao Z; Lin H
Front Physiol; 2018; 9():452. PubMed ID: 29765332
[No Abstract] [Full Text] [Related]
91. PFN2, a novel marker of unfavorable prognosis, is a potential therapeutic target involved in esophageal squamous cell carcinoma.
Cui XB; Zhang SM; Xu YX; Dang HW; Liu CX; Wang LH; Yang L; Hu JM; Liang WH; Jiang JF; Li N; Li Y; Chen YZ; Li F
J Transl Med; 2016 May; 14(1):137. PubMed ID: 27188458
[TBL] [Abstract][Full Text] [Related]
92. Identification of hub genes associated with bladder cancer using bioinformatic analyses.
Zheng W; Zhao Y; Wang T; Zhao X; Tan Z
Transl Cancer Res; 2022 May; 11(5):1330-1343. PubMed ID: 35706790
[TBL] [Abstract][Full Text] [Related]
93. LZTS2: A novel and independent prognostic biomarker for clear cell renal cell carcinoma.
Peng Y; Greenland NY; Lang UE; Stohr BA
Pathol Res Pract; 2022 Apr; 232():153831. PubMed ID: 35287088
[TBL] [Abstract][Full Text] [Related]
94. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y
Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107
[TBL] [Abstract][Full Text] [Related]
95. Pan-cancer analyses identify MIR210HG overexpression, epigenetic regulation and oncogenic role in human tumors and its interaction with the tumor microenvironment.
Yadav G; Kulshreshtha R
Life Sci; 2024 Feb; 339():122438. PubMed ID: 38242493
[TBL] [Abstract][Full Text] [Related]
96. ARPC2: A Pan-Cancer Prognostic and Immunological Biomarker That Promotes Hepatocellular Carcinoma Cell Proliferation and Invasion.
Huang S; Dong C; Li D; Xu Y; Wu J
Front Cell Dev Biol; 2022; 10():896080. PubMed ID: 35733852
[No Abstract] [Full Text] [Related]
97. Overexpression of kinesin superfamily members as prognostic biomarkers of breast cancer.
Li TF; Zeng HJ; Shan Z; Ye RY; Cheang TY; Zhang YJ; Lu SH; Zhang Q; Shao N; Lin Y
Cancer Cell Int; 2020; 20():123. PubMed ID: 32322170
[TBL] [Abstract][Full Text] [Related]
98. The mu-opioid receptor is a molecular marker for poor prognosis in hepatocellular carcinoma and represents a potential therapeutic target.
Chen DT; Pan JH; Chen YH; Xing W; Yan Y; Yuan YF; Zeng WA
Br J Anaesth; 2019 Jun; 122(6):e157-e167. PubMed ID: 30915986
[TBL] [Abstract][Full Text] [Related]
99. Cyclin-Dependent Kinase Regulatory Subunit 2 Indicated Poor Prognosis and Facilitated Aggressive Phenotype of Hepatocellular Carcinoma.
Zhang J; Song Q; Liu J; Lu L; Xu Y; Zheng W
Dis Markers; 2019; 2019():8964015. PubMed ID: 31781310
[TBL] [Abstract][Full Text] [Related]
100. A complex of Kif18b and MCAK promotes microtubule depolymerization and is negatively regulated by Aurora kinases.
Tanenbaum ME; Macurek L; van der Vaart B; Galli M; Akhmanova A; Medema RH
Curr Biol; 2011 Aug; 21(16):1356-65. PubMed ID: 21820309
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
